Key result
Only ~68% of patients with AF and CKD receive correct DOAC dosing.
Why the study?
CKD and AF are increasing in prevalence globally, prompting an evaluation of real-world DOAC prescribing in terms of adherence, persistence, and renal dose titration.
Meta-Analysis (n=252,117)
DOAC adherence and appropriate dose adjustments are suboptimal in patients with concurrent atrial fibrillation and chronic kidney disease, highlighting a significant prescribing gap.
Answers are grounded in this paper and cite their sources.
Suboptimal DOAC dosing and adherence in AF with CKD warrant closer monitoring; extends documentation of real-world prescribing gaps.
BACKGROUND: Chronic kidney disease (CKD) and atrial fibrillation (AF) are increasing in prevalence globally and share common risk factors.Our aim was to characterise real-world evidence on direct oral anticoagulant (DOAC) prescribing for people with AF and CKD, in terms of adherence, persistence and renal dose titration. METHODS: PubMed, EMBASE and CINAHL were searched from inception to June 2022. Our search terms included a combination of Medical Subject Headings (MeSH) terms and keywords including 'atrial fibrillation', 'chronic kidney disease', 'adherence', 'persistence', 'direct oral anticoagulants' and 'dosing'. Data extraction and quality assessment were undertaken by two reviewers independently. Meta-analyses for pooled estimates were performed using DerSimonian and Laird random-effects models. Age, sex, diabetes, hypertension and heart failure were chosen as variables of interest. RESULTS: From 19 studies, a total of 252 117 patients were included with CKD and AF. Meta-analysis was only possible in seven studies with 128 406 patients, five on DOAC dose titration and two on adherence. There were insufficient studies on persistence. Our meta-analysis of dosing showed that 68% of patients with CKD and AF had correct dosing. There was no evidence to show any association between correct DOAC dosing and variables of interest. Overall, 67% of patients were DOAC adherent. CONCLUSION: Adherence and correct dosing of DOACs were suboptimal compared with other medications in the pooled studies with respect to CKD and AF. Thus, further research is required as the lack of generalisation of findings is a rate-limiting factor for improved DOAC management in AF and CKD. PROSPERO REGISTRATION NUMBER: CRD;42022344491.
No takes yet. Share an insight, caveat, or question.
Emanuel et al. (2023) conducted a meta-analysis in Atrial fibrillation and chronic kidney disease (n=252,117). Direct oral anticoagulants (DOACs) was evaluated on Correct DOAC dosing (fidelity of prescribing to recommended doses in CKD). In a meta-analysis of patients with atrial fibrillation and chronic kidney disease, only 68% received correct DOAC dosing and 67% were adherent to DOAC therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: